Physician profile
John Kern
NPI 1588930879
$2,707.47
in general payments reported to CMS, 2019-2025
25 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2021: $41.92 · 2022: $107 · 2023: $660 · 2024: $668 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.43 |
| Education | $118.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $754.68 | 2019-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $417.13 | 2024-2025 | Airsupra, Tezspire, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $229.90 | 2022-2023 | |
| Genzyme Corporation | $229.07 | 2024-2025 | |
| Glaxosmithkline, LLC. | $175.44 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inari Medical, INC. | $107.18 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.60 | 2019-2025 | Ofev |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $70.37 | 2024-2025 | Dupixent |
| Philips North America LLC | $66.16 | 2023-2025 | (Ak6) Vest Therapy, Mcot |
| Insmed, INC. | $57.11 | 2025 | Brinsupri, Arikayce |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.92 | 2022-2023 | Lifevest |
| Baxter Healthcare | $42.04 | 2025 | Perclot |
| Edwards Lifesciences Corporation | $41.92 | 2021 | |
| Axsome Therapeutics, INC. | $40.75 | 2025 | Auvelity, Sunosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $33.12 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.78 | 2023 | Aralast |
| Scpharmaceuticals INC. | $23.88 | 2024 | |
| Abiomed | $22.39 | 2023 | Impella |
| Genentech USA, INC. | $20.68 | 2025 | Xolair |
| United Therapeutics Corporation | $19.53 | 2024 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $18.96 | 2024 | Lumryz |
| Harmony Biosciences LLC | $18.38 | 2025 | |
| Merck Sharp & Dohme LLC | $16.75 | 2024 | Verquvo |
| Lilly USA, LLC | $14.78 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.